Gossamer Calls It Quits On BTK Inhibitor Following Patient Deaths

 
• By Alaric DeArment
  
Gossamer is prioritizing seralutinib in pulmonary arterial hypertension after deciding to discontinue GB5121 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D